Pralatrexate produced clear concentration-dependent inhibition of recombinant human DHFR in a cell-free system, with an apparent inhibition constant of 45 nM. In PC3 prostate cancer cells, exposure to increasing concentrations for 72 h followed by compound-free medium for 48 h yielded an MTT cell viability IC50 of 0.01±0.002 μM. In RH4 cells cultured for 96 h, Pralatrexate exhibited the lowest mean IC50 (0.3712 nM) and maximal growth inhibition (nearly 100%) of all tested drugs. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Pralatrexate inhibition of recombinant human DHFR
Biochemical assay · recombinant human DHFR [1]
In a cell-free system containing recombinant human DHFR, pralatrexate produced clear concentration-dependent inhibition of activity, with an apparent inhibition constant of 45 nM.
Literature-Reported Treatment Conditions
- Method
- cell-free system
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Pralatrexate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Enzyme activity assays (S5); Results (S29, S30, S31, S33, S34)
apparent inhibition constants (Ki app) of DHFR inhibition: apparent inhibition constants (Ki app) of DHFR inhibition; comparator: absence of pralatrexate — Results (S31, S33, S34)
Cell viability response in prostate cancer cells
Cell-based study · prostate cancer cell line PC3 [2]
PC3 prostate cancer cells were exposed to increasing concentrations of Pralatrexate for 72 h, followed by compound-free medium for 48 h. Cell viability assessed by MTT assay yielded an IC50 of 0.01±0.002 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- increasing concentrations
- Exposure duration
- 72 h; compound-free medium for 48 h
- Method
- exposed to pralatrexate
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Pralatrexate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cytotoxicity assays (S5, S7, S9, S11, S12); Results > Single-agent antiproliferative effects (S34, S35); Table 1 legend (S102)
cell viability; MTT assay: cell viability; MTT assay; comparator: untreated cells — Materials and methods > Cytotoxicity assays (S5); Results > Single-agent antiproliferative effects (S35); Table 1 legend (S102)
Growth inhibition in cultured tumor cells
Cell-based study · RH4 cells [3]
RH4 cells were cultured with increasing concentrations of Pralatrexate for 96 h, with metabolically active cells measured. Pralatrexate exhibited the lowest mean IC50 (0.3712 nM) and maximal growth inhibition (nearly 100%) of all tested drugs.
Literature-Reported Treatment Conditions
- Exposure duration
- 96 h
- Method
- culturing RH4 cells in the presence of increasing concentrations
- Reported limits
- Not stated in the sentences used: dose, vehicle, control.
Methods and source locations
Compound reported in the paper: Pralatrexate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > FP-RMS cell lines are sensitive to pralatrexate (S323, S324)
number of metabolically active cells: number of metabolically active cells — Results > FP-RMS cell lines are sensitive to pralatrexate (S323, S324)